BofA on Amgen (AMGN): 'Catalysts: pelacarsen readthrough shifts to mid-2026'

BofA Securities analyst Tazeen Ahmad reiterated an Underperform rating and $304.00 price target on Amgen (NASDAQ: AMGN).

The analyst comments "Important upcoming catalysts include (1) detailed MariTide Ph 2 update (2026 TBD); (2) Ionis/Novartis' Ph 3 pelacarsen Lp(a) HORIZON CVOT readout (now mid-‘26 – event driven, readthrough to olpasiran); (3) AMG 513 Ph 1 readout in obesity (PCD Jul 2026); (4) MariTide Ph 3 readouts (starting in 2027); and (5) olpasiran Ph 3 readout (2027)."

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $338.59 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters